Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1157/13115105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating concerns for perampanel in the treatment of pediatric Dravet syndrome.
Transl Pediatr
December 2024
Karachi Medical and Dental College, Karachi, Pakistan.
Improving breast cancer treatments using pharmacomicrobiomics.
mBio
January 2025
Center for Gastrointestinal Biology and Disease and Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Tamoxifen is the mainstay treatment for estrogen-positive breast cancer for over half a century. However, a significant proportion of patients experience disease recurrence due to treatment failure attributed to various factors, including disease pathology, genetics, and drug metabolism. Alam et al.
View Article and Find Full Text PDFCurrent status of drug therapy for chronic hepatitis B.
World J Gastroenterol
January 2025
Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
In this editorial, we comment on the article by Meng . Chronic hepatitis B (CHB) is a significant global health problem, particularly in developing countries. Hepatitis B virus (HBV) infection is one of the most important risk factors for cirrhosis and hepatocellular carcinoma.
View Article and Find Full Text PDFProspects of elafibranor in treating alcohol-associated liver diseases.
World J Gastroenterol
January 2025
School of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China.
Alcohol-related liver disease (ALD), which is induced by excessive alcohol consumption, is a leading cause of liver-related morbidity and mortality. ALD patients exhibit a spectrum of liver injuries, including hepatic steatosis, inflammation, and fibrosis, similar to symptoms of nonalcohol-associated liver diseases such as primary biliary cholangitis, metabolic dysfunction-associated steatotic liver disease, and nonalcoholic steatohepatitis. Elafibranor has been approved for the treatment of primary biliary cholangitis and has been shown to improve symptoms in both animal models and cell models of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis.
View Article and Find Full Text PDFPotential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter].
Drug Des Devel Ther
January 2025
Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!